Doxorubicin (Dox) is one of the most commonly used anthracyclines for the treatment of solid and hematological tumors such as B-/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II enzyme functionality, thus inducing structural damages during DNA replication and causes direct damages intercalating into DNA double helix. Eukaryotic cells respond to DNA damages by activating the ATM-CHK2 and/or ATR-CHK1 pathway, whose function is to regulate cell cycle progression, to promote damage repair, and to control apoptosis. We evaluated the efficacy of a new drug schedule combining Dox and specific ATR (VE-821) or CHK1 (prexasertib, PX) inhibitors in the treatment of human B-/T cell precursor ALL cell lines and primary ALL leukemic cells. We found that ALL cell lines respond to Dox activating the G2/M cell cycle checkpoint. Exposure of Dox-pretreated ALL cell lines to VE-821 or PX enhanced Dox cytotoxic effect. This phenomenon was associated with the abrogation of the G2/M cell cycle checkpoint with changes in the expression pCDK1 and cyclin B1, and cell entry in mitosis, followed by the induction of apoptosis. Indeed, the inhibition of the G2/M checkpoint led to a significant increment of normal and aberrant mitotic cells, including those showing tripolar spindles, metaphases with lagging chromosomes, and massive chromosomes fragmentation. In conclusion, we found that the ATR-CHK1 pathway is involved in the response to Dox-induced DNA damages and we demonstrated that our new in vitro drug schedule that combines Dox followed by ATR/CHK1 inhibitors can increase Dox cytotoxicity against ALL cells, while using lower drug doses. • Doxorubicin activates the G2/M cell cycle checkpoint in acute lymphoblastic leukemia (ALL) cells. • ALL cells respond to doxorubicin-induced DNA damages by activating the ATR-CHK1 pathway. • The inhibition of the ATR-CHK1 pathway synergizes with doxorubicin in the induction of cytotoxicity in ALL cells. • The inhibition of ATR-CHK1 pathway induces aberrant chromosome segregation and mitotic spindle defects in doxorubicin-pretreated ALL cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406704PMC
http://dx.doi.org/10.1007/s10565-021-09640-xDOI Listing

Publication Analysis

Top Keywords

atr-chk1 pathway
24
dna damages
16
cell cycle
16
acute lymphoblastic
12
lymphoblastic leukemia
12
cell lines
12
g2/m cell
12
cycle checkpoint
12
cell
10
cells
9

Similar Publications

Hepatitis B virus hijacks MRE11-RAD50-NBS1 complex to form its minichromosome.

PLoS Pathog

January 2025

State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology, Institute of Medical Virology, TaiKang Medical School, Wuhan University, Wuhan, China.

Chronic hepatitis B virus (HBV) infection can significantly increase the incidence of cirrhosis and liver cancer, and there is no curative treatment. The persistence of HBV covalently closed circular DNA (cccDNA) is the major obstacle of antiviral treatments. cccDNA is formed through repairing viral partially double-stranded relaxed circular DNA (rcDNA) by varies host factors.

View Article and Find Full Text PDF

Immune checkpoint inhibitors against PD-1/PD-L1 are highly effective in immunologically hot tumours such as triple-negative breast cancer, wherein constitutive DNA damage promotes inflammation, while inducing PD-L1 expression to avoid attack by cytotoxic T cells. However, whether and how PD-L1 regulates the DNA damage response and inflammation remains unclear. Here, we show that nuclear PD-L1 activates the ATR-Chk1 pathway and induces proinflammatory chemocytokines upon genotoxic stress.

View Article and Find Full Text PDF

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2 ovarian cancer models.

Biochim Biophys Acta Mol Basis Dis

February 2025

Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland. Electronic address:

Article Synopsis
  • Olaparib resistance in ovarian cancer patients calls for new strategies, leading to the creation of a patient-derived xenograft model to study this issue.
  • In experiments, olaparib-resistant tumors were treated with olaparib alone, or combined with ATR and CHK1 inhibitors, revealing that these combinations effectively hindered tumor growth and altered key molecular signaling pathways.
  • The study enhances our understanding of how to combat olaparib resistance in high-grade serous ovarian cancer with BRCA1/2 mutations, suggesting that targeting the ATR/CHK1 pathways could improve treatment outcomes for patients who are initially unresponsive to olaparib.
View Article and Find Full Text PDF
Article Synopsis
  • * Targeted therapies, like PARP inhibitors, have shown promise in treating cancers with specific DDR defects, such as mutations in BRCA1 or BRCA2, by taking advantage of vulnerabilities through synthetic lethality.
  • * Ongoing research aims to identify new DDR therapeutic targets and improve treatment strategies by optimizing therapies, understanding resistance mechanisms, and combining them with other treatment modalities.
View Article and Find Full Text PDF
Article Synopsis
  • Oncogenic mutations like those in KRAS cause transcription-replication conflicts (TRCs) in pancreatic ductal adenocarcinoma (PDAC), making them more common in these cancer cells than in other tumors or normal cells.
  • The study identifies base-excision repair (BER) factors as key regulators of TRCs, with BER inhibitors increasing TRCs by disrupting RNA polymerase II and R-loop dynamics.
  • Combining ATR and BER inhibitors shows promise in enhancing DNA damage and reducing PDAC cell growth, emphasizing the therapeutic potential of targeting these pathways in cancer treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!